There are two mechanisms of damage after spinal cord injury (SCI): a primary mechanical injury and a secondary injury mediated by multiple processes after the initial trauma. The outcomes of SCI depend mainly on the extent of secondary damage produced by a series of cellular and molecular events, such as inflammation, free radical production, and glutamate (Glu) excitotoxicity, which inevitably induce neuronal and glial cell death at and beyond the site of injury. To date, there is no effective treatment for SCI; therefore, developing novel therapeutic strategies for SCI is highly prioritized.Ginkgo biloba extract (EGb761) is a complex mixture of ingredients with broad pharmacological effects on the CNS. Recent studies on SCI revealed that EGb761 was involved in protection of spinal cord neurons in ischemic injury (Mechirova et al. 2009)
AbstractGinkgo biloba extract (EGb761) has been shown to be neuroprotective; however, the mechanism by which EGb761 mediates neuroprotection remains unclear. We hypothesized that the neuroprotective effect of EGb761 is mediated by inhibition of cytosolic phospholipase A 2 (cPLA 2 ), an enzyme that is known to play a key role in mediating secondary pathogenesis after acute spinal cord injury (SCI). To determine whether EGb761 neuroprotection involves the cPLA 2 pathway, we first investigated the effect of glutamate and hydrogen peroxide on cPLA 2 activation. Results showed that both insults induced an increase in the expression of phosphorylated cPLA 2 (p-cPLA 2 ), a marker of cPLA 2 activation, and neuronal death in vitro. Such effects were significantly reversed by EGb761 administration. Additionally, EGb761 significantly decreased prostaglandin E 2 (PGE 2 ) release, a downstream metabolite of cPLA 2 . Moreover, inhibition of cPLA 2 activity with arachidonyl trifluromethyl ketone improved neuroprotection against glutamate and hydrogen peroxideinduced neuronal death, and reversed Bcl-2/Bax ratio; notably, EGb761 produced greater effects than arachidonyl trifluromethyl ketone. Finally, we showed that the extracellular signal-regulated kinase 1/2 signaling pathway is involved in EGb761's modulation of cPLA 2 phosphorylation. These results collectively suggest that the protective effect of EGb761 is mediated, at least in part, through inhibition of cPLA 2 activation, and that the extracellular signal-regulated kinase 1/2 signaling pathway may play an important role in mediating the EGb761's effect.